Cost of Opioid Crisis ‘Dwarfs’ Drugmakers’ Resources, N.Y. Says
(Bloomberg) -- The public cost of coping with the opioid crisis in the U.S. “dwarfs” the combined resources of the companies sued for allegedly causing the epidemic, including OxyContin maker Purdue Pharma LP, a lawyer for New York State told a judge.
“That's the reality of the opioid litigation,” David Nachman, a lawyer for New York Attorney General Letitia James, said at a hearing Monday in Central Islip, New York, where dozens of lawsuits filed in the state against about 80 defendants have been consolidated.
State Supreme Court Justice Jerry Garguilo is weighing requests to dismiss New York's lawsuit against Purdue and its owners, the billionaire Sackler family, as well as groups of manufacturers, distributors and other defendants who contend they've been wrongfully accused.
Nachman made the comment about possible damages in the case after the judge asked him whether the total public cost of the crisis should be estimated before a trial set for April or May, as some of the parties have argued.
“We think the number is so large that it's not going to be meaningful,” Nachman said.
The judge declined to hear arguments from Purdue and the Sacklers for now, citing a hearing Friday in a New York bankruptcy court in which their lawyers will argue that all litigation against them should be blocked as a result of the company's mid-September filing for protection from creditors. Purdue wants the injunction extended to cover its owners.
Read More: Opioid Settlement Encourages Sale of More Opioids, Critics Say
Lawyers for Purdue and the Sacklers have denied wrongdoing and argue that halting litigation will preserve the value of the company and allow them to move forward with a proposed settlement valued at $10 billion, including at least $3 billion from the Sacklers. About half the states involved, including New York, have rejected the deal.
Lawyers for the manufacturers and distributors told the judge on Monday that the claims against them should be dismissed because the state failed to establish that the crisis was a “public nuisance,” the central claim in New York's lawsuit.
“What's the public nuisance here?” Donna Welch, a lawyer who argued on behalf of manufacturers, asked at the hearing. “They won't say.”
To contact the reporter on this story: Erik Larson in New York at elarson4@bloomberg.net
To contact the editors responsible for this story: David Glovin at dglovin@bloomberg.net, Peter Jeffrey
©2019 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.